T. Matsuya

发表

Synthesis and evaluation of [11C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brain.

S. Nishimura, T. Matsuya, H. Takamatsu, 2005, Nuclear medicine and biology.

Drug Discovery for PTSD: Characterization of an Animal Model of PTSD and PET Imaging of Brain Glucocorticoid Receptor

T. Yamaji, S. Nishimura, N. Matsuoka, 2006 .

Quantitation of cardiac sympathetic innervation in rabbits using 11C-hydroxyephedrine PET: relation to 123I-MIBG uptake

S. Nekolla, K. Nakajima, J. Taki, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression

S. Kuromitsu, Masaaki Hirano, Hiroko Yamamoto, 2019, Molecular Cancer Therapeutics.

Abstract 1728: ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations

S. Kuromitsu, Masaaki Hirano, Hiroko Yamamoto, 2014 .

Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model.

S. Nishimura, S. Miyoshi, K. Yamanaka, 2013, Nuclear medicine and biology.

Neural Circuits Containing Pallidotegmental GABAergic Neurons are Involved in the Prepulse Inhibition of the Startle Reflex in Mice

T. Nabeshima, H. Mizoguchi, T. Nagai, 2007, Biological Psychiatry.

Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.

Masaaki Hirano, N. Kaneko, H. Koshio, 2019, Leukemia research.

Abstract 2586: ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models

S. Kuromitsu, Masaaki Hirano, Hiroko Yamamoto, 2015 .

Synthesis and structure-activity relationships of pyrazine-2-carboxamide derivatives as novel echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) inhibitors.

Kazuhiko Iikubo, Yoshinori Iwai, Ayako Moritomo, 2019, Bioorganic & medicinal chemistry.

Brain Adenosine A2A Receptor Occupancy by a Novel A1/A2A Receptor Antagonist, ASP5854, in Rhesus Monkeys: Relationship to Anticataleptic Effect

A. Iwashita, S. Nishimura, S. Miyoshi, 2008, Journal of Nuclear Medicine.

Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.

M. Asai, H. Mizoguchi, T. Nagai, 2007, Journal of pharmacological sciences.

suppressant, in a human prostate tumor-xenograft mouse model

S. Nishimura, S. Miyoshi, K. Yamanaka, 2013 .

Synthesis and evaluation of [11C]RU40555, a selective glucocorticoid receptor antagonist

S. Nishimura, T. Matsuya, H. Takamatsu, 2005 .

Involvement of hippocampal extracellular signal-regulated kinase 1/2 in spatial working memory in rats

T. Nabeshima, T. Nagai, Kiyofumi Yamada, 2006, Neuroreport.

Brain Adenosine A2A Receptor Occupancy by a Novel A1/A2A Receptor Antagonist, ASP5854, in Rhesus Monkeys: Relationship to Anticataleptic Effect

A. Iwashita, S. Nishimura, S. Miyoshi, 2008, Journal of Nuclear Medicine.